These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26946633)

  • 41. Human papillomavirus vaccine efficacy: aligning expectations with reality.
    Smith-McCune KK
    Gynecol Oncol; 2008 Oct; 111(1):1-2. PubMed ID: 18922296
    [No Abstract]   [Full Text] [Related]  

  • 42. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gynaecological cancer: HPV vaccine: is age just a number?
    Stone L
    Nat Rev Urol; 2014 Nov; 11(11):605. PubMed ID: 25245243
    [No Abstract]   [Full Text] [Related]  

  • 44. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness.
    Coupé VM; van Ginkel J; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
    Int J Cancer; 2009 Feb; 124(4):970-8. PubMed ID: 19035448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Current immunization committee includes vaccination against human papillomaviruses in the immunization schedule].
    Kinderkrankenschwester; 2007 May; 26(5):205. PubMed ID: 17550093
    [No Abstract]   [Full Text] [Related]  

  • 46. [Vaccination against human papillomaviridae. Expert correspondence no. 18 of 29 December 2006].
    Kommission Qualitätssicherung der Schweizerischen Gesellschaft für Gynäkologie und Geburtshilfe
    Gynakol Geburtshilfliche Rundsch; 2007; 47(2):101-2. PubMed ID: 17440273
    [No Abstract]   [Full Text] [Related]  

  • 47. Success of HPV vaccination is now a matter of coverage.
    Schiffman M; Wacholder S
    Lancet Oncol; 2012 Jan; 13(1):10-2. PubMed ID: 22075169
    [No Abstract]   [Full Text] [Related]  

  • 48. [Swedish consensus on cervix cancer vaccination. Vaccination programs for eradication of HPV16/18 should be initiated in elementary schools].
    Dillner J; Andrae B; Westermark B
    Lakartidningen; 2006 Nov 1-7; 103(44):3377-9. PubMed ID: 17152260
    [No Abstract]   [Full Text] [Related]  

  • 49. Human papilloma virus vaccine and a few facts.
    Puwar T; Puwar B
    Indian J Med Sci; 2009 Jul; 63(7):309-10. PubMed ID: 19700913
    [No Abstract]   [Full Text] [Related]  

  • 50. Primary and secondary prevention of cervical cancer--opportunities and challenges.
    Markowitz LE; Unger ER; Saraiya M
    J Natl Cancer Inst; 2009 Apr; 101(7):439-40. PubMed ID: 19318638
    [No Abstract]   [Full Text] [Related]  

  • 51. HPV vaccination: for women of all ages?
    Castle PE; Schmeler KM
    Lancet; 2014 Dec; 384(9961):2178-80. PubMed ID: 25189357
    [No Abstract]   [Full Text] [Related]  

  • 52. [Vaccine against human papillomavirus : PATRICIA Study (PApilloma TRIal against Cancer In young Adults)].
    Kaufmann AM; Nitschmann S
    Internist (Berl); 2010 Mar; 51(3):410, 412-3. PubMed ID: 20127302
    [No Abstract]   [Full Text] [Related]  

  • 53. Prospects for cervical cancer prevention by human papillomavirus vaccination.
    Schiller JT; Lowy DR
    Cancer Res; 2006 Nov; 66(21):10229-32. PubMed ID: 17079437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women.
    Levi M; Bonanni P; Burroni E; Bechini A; Boccalini S; Sani C; Bonaiuti R; Indiani L; Azzari C; Lippi F; Carozzi F;
    Hum Vaccin Immunother; 2013 Jul; 9(7):1407-12. PubMed ID: 23571176
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica.
    Coseo S; Porras C; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Wang SS; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
    Sex Transm Dis; 2010 Nov; 37(11):706-14. PubMed ID: 20661178
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-clinical safety assessment of single and repeated intramuscular administration of a human papillomavirus-16/18 vaccine in rabbits and rats.
    Segal L; Morelle D; Kaaber K; Destexhe E; Garçon N
    J Appl Toxicol; 2015 Dec; 35(12):1577-85. PubMed ID: 25752809
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
    Goldie SJ; Kim JJ; Kobus K; Goldhaber-Fiebert JD; Salomon J; O'shea MK; Xavier Bosch F; de Sanjosé S; Franco EL
    Vaccine; 2007 Aug; 25(33):6257-70. PubMed ID: 17606315
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CDC panel backs routine HPV vaccination.
    Kuehn BM
    JAMA; 2006 Aug; 296(6):640-1. PubMed ID: 16896097
    [No Abstract]   [Full Text] [Related]  

  • 59. Age of human papillomavirus vaccination?
    Castle PE; Burger EA
    Lancet Infect Dis; 2016 Oct; 16(10):1091-1093. PubMed ID: 27373899
    [No Abstract]   [Full Text] [Related]  

  • 60. Early impact of the Japanese immunization program implemented before the HPV vaccination crisis.
    Matsumoto K; Yaegashi N; Iwata T; Yamamoto K; Nagashima M; Saito T; Ushijima K; Takahashi F; Noda K; Yoshikawa H
    Int J Cancer; 2017 Oct; 141(8):1704-1706. PubMed ID: 28657110
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.